RSV Vaccine Uptake Remains Low Among US Veterans, Study Finds

Infectious Disease Advisor (8/15, Basilio) reported a study found that “respiratory syncytial virus (RSV) vaccine uptake among veterans remains lower than the national average, despite the older age and comorbidities present in this population.” Researchers observed that “of the 3,497,851 vaccine-eligible veterans during the 2023 to 2024 season, 9.8% received an RSV vaccine; of the 2,757,249 veterans eligible during the 2024 to 2025 season, 3.0% received the vaccine during the first 4 months of the season. Vaccine uptake was lower among individuals who underwent all virtual visits when compared with those who had at least 1 in-person visit across both seasons.” The study was published in Open Forum Infectious Diseases.